Research and Markets (http://www.researchandmarkets.com/research/mplzf5/venous_leg_ulcers) has announced the addition of the "Venous Leg Ulcers (Crural ulcer) - Pipeline Review, H1 2015" report to their offering.
This report provides comprehensive information on the therapeutic development for Venous Leg Ulcers (Crural ulcer), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Venous Leg Ulcers (Crural ulcer) and special features on late-stage and discontinued projects.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Companies Involved in Therapeutics Development
- Adocia
- CardioVascular BioTherapeutics, Inc.
- CoDa Therapeutics, Inc.
- CytoTools AG
- FirstString Research, Inc.
- Intralytix, Inc.
- MacroCure Ltd.
- Pergamum AB
- RegeneRx Biopharmaceuticals, Inc.
- Smith & Nephew Plc
- Stratatech Corporation
Drug Profiles
- Cathelicidin
- Cell Therapy to Activate VEGF for Venous Leg Ulcers and Diabetic Foot Ulcers
- CL-05
- CODA-001
- CureXcell
- CVBT-141B
- Granexin
- HP-802247
- LL-37
- Recombinant Protein to Agonize Platelet Derived Growth Factor Receptor for Metabolic and Dermatology Diseases
- RGN-137
- WPP-201
For more information visit http://www.researchandmarkets.com/research/mplzf5/venous_leg_ulcers
Contacts:
Laura Wood, Senior Manager
press@researchandmarkets.com
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S.
Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Pharmaceuticals
